Tumor lysis syndrome
References (25)
- et al.
Nephropathy, xanthinuria, and orotic aciduria complicating Burkitt's lymphoma treated with chemotherapy and allopurinol
Metabolism
(1972) Tumor lysis syndrome
- et al.
Oncologic emergencies in the patient with lymphoma
Critical care issues in the patient with hematologic malignancy
- et al.
High-level production of a peroxisomal enzyme: Aspergillus flavus uricase accumulates intracellularly and is active in Saccharomyces cerevisiae
Gene
(1992) - et al.
Urate-oxidase prophylaxis of uric acid-induced renal damage in childhood leukemia
J Pediatr
(1982) - et al.
Tumor lysis syndrome
- et al.
Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol
N Engl J Med
(1970) - et al.
Acute tumour lysis syndrome
Br J Hosp Med
(1993) Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy
Cancer Metastasis Rev
(1999)
Acute tumor lysis syndrome in hematologic malignancies
Leuk Lymphoma
Metabolic emergencies in the cancer patient
Cited by (125)
Tumor Lysis Syndrome
2021, Advances in Chronic Kidney DiseaseDiagnostic potential of major and trace elements in the serum of bladder cancer patients
2018, Journal of Trace Elements in Medicine and BiologyElevated uric acid and adenosine triphosphate concentrations in bronchoalveolar lavage fluid of eosinophilic pneumonia
2017, Allergology InternationalCitation Excerpt :DAMPs, induced by tissue injury, interact predominantly with host pattern recognition receptors and induce inflammation and immune responses.11–13 Among known DAMPs, the role of UA in the development of immune responses has been highlighted.16,22–28 UA is a major endogenous danger signal released from injured cells, and large concentrations of UA can be produced in vivo.22,23
Challenges and opportunities for monoclonal antibody therapy in veterinary oncology
2016, Veterinary JournalCitation Excerpt :The second type of possible reactions is dependent on antibody activity. One possible effect of mAbs is the formation of tumour lysis syndrome, where the release of intracellular contents from the tumour after being targeted by treatment leads to metabolic disorders, such as hyperkalaemia, hyperphosphataemia and hypocalcaemia (Jeha, 2001; Gilbert and Wright, 2015). Undesired antibody activity has led to life threatening situations in the famous case of the CD28 superagonist antibody TGN1412, used with the goal of stimulating immune responses.
Spontaneous tumor lysis syndrome in the setting of small cell lung cancer: Report of two cases and review of the literature
2016, Cancer Treatment and Research CommunicationsTumor Lysis Syndrome
2013, Renal Disease in Cancer Patients
- 1
Dr. Jeha receives grant and research support from Sanofi-Synthélabo. She is also a consultant for and a member of the Sanofi-Synthélabo Speakers Bureau.